Browsing by Author "Piñero González, Janet, 1977-"

Sort by: Order: Results:

  • A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug-induced toxicity
    Gall, Louis; Jardí Pujol, Ferran; Lammens, Lieve; Piñero González, Janet, 1977-; Souza, Terezinha; Rodrigues, Daniela; Jennen, Danyel; de Kok, Theo M.; Coyle, Luke; Chung, Seung-Wook; Ferreira, Sofia; Jo, Heeseung; Beattie, Kylie A.; Kelly, Colette; Duckworth, Carrie A.; Pritchard, Mark; Pin, Carmen (Wiley, 2023)
    We have built a quantitative systems toxicology modeling framework focused on the early prediction of oncotherapeutic-induced clinical intestinal adverse effects. The model describes stem and progenitor cell dynamics in ...
  • A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk
    Gomez-Rubio, P.; Piñero González, Janet, 1977-; Ilzarbe Sánchez, Lucas; Iglesias Coma, Mar; Poves Prim, José Ignacio; Real, Francisco X.; PanGenEU Study Investigators (Oxford University Press, 2017)
    BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed in late adulthood; therefore, many patients suffer or have suffered from other diseases. Identifying disease patterns associated with PDAC risk may ...
  • An ensemble learning approach for modeling the systems biology of drug-induced injury
    Aguirre Plans, Joaquim, 1993-; Piñero González, Janet, 1977-; Souza, Terezinha; Callegaro, Giulia; Kunnen, Steven J.; Sanz, Ferran; Fernández Fuentes, Narcís; Furlong, Laura I., 1971-; Guney, Emre; Oliva Miguel, Baldomero (BioMed Central, 2021)
    Background: Drug-induced liver injury (DILI) is an adverse reaction caused by the intake of drugs of common use that produces liver damage. The impact of DILI is estimated to affect around 20 in 100,000 inhabitants worldwide ...
  • Automatic filtering and substantiation of drug safety signals
    Bauer-Mehren, Anna; van Mulligen, Erik M.; Avillach, Paul; Carrascosa Baena, María Carmen, 1972-; García Serna, Ricard; Piñero González, Janet, 1977-; Singh, Barat; Lopes, Pedro; Oliveira, José Luis; Diallo, Gayo; Ahlberg Helgee, Ernst; Boyer, Scott; Mestres i López, Jordi; Sanz, Ferran; Kors, Jan A.; Furlong, Laura I., 1971- (Public Library of Science (PLoS), 2012)
    Drug safety issues pose serious health threats to the population and constitute a major cause of mortality worldwide. Due to the prominent implications to both public health and the pharmaceutical industry, it is of great ...
  • Benchmarking post-GWAS analysis tools in major depression: Challenges and implications
    Pérez-Granado, Judith; Piñero González, Janet, 1977-; Furlong, Laura I., 1971- (Frontiers, 2022)
    Our knowledge of complex disorders has increased in the last years thanks to the identification of genetic variants (GVs) significantly associated with disease phenotypes by genome-wide association studies (GWAS). However, ...
  • Capturing variation impact on molecular interactions in the IMEx Consortium mutations data set
    Del Toro, N.; Piñero González, Janet, 1977-; Furlong, Laura I., 1971-; Porras, P.; IMEx Consortium Curators (Nature Research, 2019)
    The current wealth of genomic variation data identified at nucleotide level presents the challenge of understanding by which mechanisms amino acid variation affects cellular processes. These effects may manifest as distinct ...
  • Comorbidity between Alzheimer's disease and major depression: a behavioural and transcriptomic characterization study in mice
    Martín Sánchez, Ana; Piñero González, Janet, 1977-; Nonell Mazelon, Lara, 1972-; Arnal, Magdalena; Ribe, Elena; Nevado-Holgado, Alejo J.; Lovestone, Simon; Sanz, Ferran; Furlong, Laura I., 1971-; Valverde, Olga (BioMed Central, 2021)
    Background: Major depression (MD) is the most prevalent psychiatric disease in the population and is considered a prodromal stage of the Alzheimer's disease (AD). Despite both diseases having a robust genetic component, ...
  • DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases.
    Queralt Rosinach, Núria; Piñero González, Janet, 1977-; Bravo Serrano, Àlex, 1984-; Sanz, Ferran; Furlong, Laura I., 1971- (Oxford University Press , 2016)
    MOTIVATION: DisGeNET-RDF makes available knowledge on the genetic basis of human diseases in the Semantic Web. Gene-disease associations (GDAs) and their provenance metadata are published as human-readable and machine-processable ...
  • DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants
    Piñero González, Janet, 1977-; Bravo Serrano, Àlex, 1984-; Queralt Rosinach, Núria; Gutiérrez Sacristán, Alba; Déu Pons, Jordi; Centeno, Emilio; García-García, Javier, 1982-; Sanz, Ferran; Furlong, Laura I., 1971- (Oxford University Press, 2017)
    The information about the genetic basis of human diseases lies at the heart of precision medicine and drug discovery. However, to realize its full potential to support these goals, several problems, such as fragmentation, ...
  • DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes.
    Piñero González, Janet, 1977-; Queralt Rosinach, Núria; Bravo Serrano, Àlex, 1984-; Déu Pons, Jordi; Bauer-Mehren, Anna; Baron, Martin; Sanz, Ferran; Furlong, Laura I., 1971- (Oxford University Press, 2015)
    DisGeNET is a comprehensive discovery platform designed to address a variety of questions concerning the genetic underpinning of human diseases. DisGeNET contains over 380,000 associations between >16,000 genes and 13,000 ...
  • Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches
    Niarakis, Anna; Piñero González, Janet, 1977-; Furlong, Laura I., 1971-; COVID-19 Disease Map Community (Frontiers, 2024)
    Introduction: The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions ...
  • Embracing the dark side: computational approaches to unveil the functionality of genes lacking biological annotation in drug-induced liver injury
    Souza, Terezinha; Panuwat, Trairatphisan; Piñero González, Janet, 1977-; Furlong, Laura I., 1971-; Saez-Rodriguez, Julio; Kleinjans, Jos C.; Jennen, Danyel (Frontiers, 2018)
    In toxicogenomics, functional annotation is an important step to gain additional insights into genes with aberrant expression that drive pathophysiological mechanisms. Nevertheless, there exists a gap on annotation of these ...
  • Extraction of relations between genes and diseases from text and large-scale data analysis: implications for translational research.
    Bravo Serrano, Àlex, 1984-; Piñero González, Janet, 1977-; Queralt Rosinach, Núria; Rautschka, Michael; Furlong, Laura I., 1971- (BioMed Central, 2015)
    BACKGROUND: Current biomedical research needs to leverage and exploit the large amount of information reported in scientific publications. Automated text mining approaches, in particular those aimed at finding relationships ...
  • Functional genomics analysis to disentangle the role of genetic variants in major depression
    Pérez-Granado, Judith; Piñero González, Janet, 1977-; Medina-Rivera, Alejandra; Furlong, Laura I., 1971- (MDPI, 2022)
    Understanding the molecular basis of major depression is critical for identifying new potential biomarkers and drug targets to alleviate its burden on society. Leveraging available GWAS data and functional genomic tools ...
  • Genetic and functional characterization of disease associations explains comorbidity
    Rubio Pérez, Carlota, 1990-; Güney, Emre, 1983-; Aguilar, Daniel; Piñero González, Janet, 1977-; García-García, Javier, 1982-; Iadarola, Barbara; Sanz, Ferran; Fernández Fuentes, Narcís; Furlong, Laura I., 1971-; Oliva Miguel, Baldomero (Nature Publishing Group, 2017)
    Understanding relationships between diseases, such as comorbidities, has important socio-economic implications, ranging from clinical study design to health care planning. Most studies characterize disease comorbidity using ...
  • Genomic and proteomic biomarker landscape in clinical trials
    Piñero González, Janet, 1977-; Rodriguez Fraga, Pablo S.; Valls-Margarit, Jordi; Ronzano, Francesco; Accuosto, Pablo; Lambea Jane, Ricard; Sanz, Ferran; Furlong, Laura I., 1971- (Elsevier, 2023)
    The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation ...
  • Genopyc: a Python library for investigating the functional effects of genomic variants associated to complex diseases
    Gualdi, Francesco; Oliva Miguel, Baldomero; Piñero González, Janet, 1977- (Oxford University Press, 2024)
    Motivation: Integrative Biomedicl Informatics, Research Program on Biomedical Informatics (IBI - GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu ...
  • GUILDify v2.0: a tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets
    Aguirre Plans, Joaquim, 1993-; Piñero González, Janet, 1977-; Sanz, Ferran; Furlong, Laura I., 1971-; Fernández Fuentes, Narcís; Oliva Miguel, Baldomero; Guney, Emre (Elsevier, 2019)
    The genetic basis of complex diseases involves alterations on multiple genes. Unraveling the interplay between these genetic factors is key to the discovery of new biomarkers and treatments. In 2014, we introduced GUILDify, ...
  • Identifying multiscale translational safety biomarkers using a network-based systems approach
    Callegaro, Giulia; Schimming, Johannes P.; Piñero González, Janet, 1977-; Kunnen, Steven J.; Wijaya, Lukas; Trairatphisan, Panuwat; van den Berk, Linda; Beetsma, Kim; Furlong, Laura I.; Sutherland, Jeffrey J.; Mollon, Jennifer; Stevens, James L.; van de Water, Bob (Elsevier, 2023)
    Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo ...
  • In silico models in drug development: where we are
    Piñero González, Janet, 1977-; Furlong, Laura I., 1971-; Sanz, Ferran (Elsevier, 2018)
    The use and utility of computational models in drug development has significantly grown in the last decades, fostered by the availability of high throughput datasets and new data analysis strategies. These in silico ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking